ATAmelia Anne Trant

Amelia Anne Trant

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amelia Anne Trant has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Alla Vash-Margita

    Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, United States

    3 shared publications
  • Kerin B. Adelson

    Yale University; Yale-New Haven Hospital; Smilow Cancer Hospital at Yale-New Haven, New Haven, CT

    3 shared publications
  • Mariana Espinal

    Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, United States

    3 shared publications
  • Adam Roshka

    Yale University; Yale-New Haven Hospital; Smilow Cancer Hospital at Yale-New Haven, New Haven, CT

    2 shared publications
  • Catherine A. Lyons

    Yale University; Yale-New Haven Hospital; Smilow Cancer Hospital at Yale-New Haven, New Haven, CT

    2 shared publications
  • Deepa Camenga

    Yale School of Medicine, New Haven, Connecticut

    2 shared publications

Latest Publications

  • Optimizing menstrual health and hygiene management in the U.S.: A mixed-methods study of the barriers and the role of healthcare professionals

    by Amelia A. Trant, Mariana Espinal, Edwina P. Kisanga, Alla Vash-Margita, Lisbet Lundsberg, Sangini S. Sheth, Linda Fan


  • Open Access

    The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients

    by Amelia A. Trant, Anees Chagpar, Wei Wei, Veronique Neumeister, David Rimm, Karen Stavris, Bonnie Lurie, Courtney Frederick, Liva Andrejeva, Madhavi Raghu, et al.

    Background: Black cohosh (BC) ( Cimicifuga racemosa) may prevent and treat breast cancer through anti-proliferative, pro-apoptotic, anti-estrogenic, and anti-inflammatory effects. This study sought to evaluate the effect of BC on tumor cellular proliferation, measured by Ki67 expression, in a pre-operative window trial of ductal carcinoma in situ (DCIS) patients. Methods: Patients were treated pre-operatively for 2 to 6 weeks with BC extract. Eligible subjects were those who had DCIS on core biopsy. Ki67 was measured using automated quantitative immunofluorescence (AQUA) pre/post-operatively. Ki67, tumor volume, and hormone changes were assessed with 2-sided Wilcoxon signed-rank tests, α = .05. Results: Thirty-one patients were treated for an average of 24.5 days (median 25; range 15-36). Ki67 decreased non-significantly (n = 26; P = .20; median pre-treatment 1280, post-treatment 859; range pre-treatment 175-7438, post-treatment 162-3370). Tumor volume, estradiol, and FSH did not change significantly. No grade 3 or 4 adverse events were reported. Conclusions: BC use showed no significant impact on cellular proliferation, tumor volume, or invasive disease upgrade rates in DCIS patients. It was well-tolerated, with no observed significant toxicities. Further study is needed to elucidate BC’s role in breast cancer treatment and prevention. ClinicalTrials.gov Identifier: NCT01628536 https://clinicaltrials.gov/ct2/show/NCT01628536


  • Erratum to “Menstrual Health and Hygiene among Adolescents in the United States” [Journal of Pediatric Adolescent Gynecology. 2022 Jun;35(3):277-287]

    by Amelia A Trant, Alla Vash-Margita, Deepa Camenga, Paula Braverman, Denise Wagner, Mariana Espinal, Edwina P Kisanga, Lisbeth Lundsberg, Sangini S Sheth, Linda Fan

  • Menstrual Health and Hygiene among Adolescents in the United States

    by Amelia A. Trant, Alla Vash-Margita, Deepa Camenga, Paula Braverman, Denise Wagner, Mariana Espinal, Edwina P. Kisanga, Lisbeth Lundsberg, Sangini S. Sheth, Linda Fan


  • Increasing accrual of minority patients in breast cancer clinical trials

    by Amelia A. Trant, Lucas Walz, Whitney Allen, Jose DeJesus, Christos Hatzis, Andrea Silber

    Background Black and Hispanic patients participate in clinical trials at lower rates than white patients nationally; lack of diversity in clinical trials prevents appropriate safety and efficacy testing of new treatments in these populations. Methods The Oncology Welcomes New Haven into Trials (OWN IT) initiative at the Yale Cancer Center used a multi-tiered approach to improve breast cancer minority clinical trial accrual through community focus groups, ongoing community outreach, institutional executive council representation, grand rounds presentation, and didactic lectures with healthcare providers. Eligibility criteria of breast cancer trials at Smilow Cancer Center were reviewed using clinicaltrials.gov. Also, an anonymous, 5-min survey was conducted at regular visits with Smilow Breast Center patients to gauge awareness of and access to clinical trials. Survey data were compared to the Yale Cancer Center Clinical Trials Office, Connecticut Tumor Registry, and U.S. Census records. Two-tailed Fisher’s tests were used for all analyses. Results There was a significant increase in the number of minority patients who participated in clinical trials at Smilow Cancer Center from 2016 (95/750) to 2018 (155/944) (p = 0.0325). Two hundred patients participated in the survey; response rate 92%. There was no significant difference in the rate at which patients were invited to participate in clinical trials or the rate at which they declined to participate based on race or ethnicity. Black and Hispanic patients were significantly less likely to be aware of clinical trials than white patients (p < .001). The review of eligibility criteria showed that over half of the studies reviewed had restrictions regarding increased liver function tests, and many restricted the participation of patients with other chronic conditions. Conclusions Low participation in clinical trials among black and Hispanic patients is likely multifaceted. This study indicated that there are likely structural factors at work which can be modified with institutional effort. The role of patient education regarding clinical trials and accrual should be studied further as should eligibility criteria as a potential barrier to participation.


  • Monitoring InBaskets With Feedback to Providers Enhances the Timeliness of Patient Care

    by Amelia A. Trant, Michael Strait, Rory Kaplan, Vanna Dest, Adam Roshka, Catherine A. Lyons, Kevin A. Vest, Tessa Steffen, Anne Chiang, Kerin B. Adelson

    Purpose: Electronic health records have changed providers’ workflow. Epic’s InBasket supplants traditional communication and is a central hub for clinical information. Failure to promptly complete records impairs communication and revenue collection. By tracking providers’ InBasket activities and offering feedback, we hoped to improve InBasket management and interdisciplinary communication. Methods: We created a report to track 273 providers’ InBasket activities, including ambulatory transcriptions, chart cosignatures, order cosignatures, patient calls, results, and billable encounters. The report showed how often and for how long each activity was delinquent. We completed three Plan-Do-Study-Act cycles. During cycle 1 (November to December 2015), we sent all providers automated e-mails with their monthly results. During cycle 2 (January to April 2016), we focused solely on billable encounter closure and sent targeted e-mails to providers with > 50 delinquent encounters. The e-mails stated that providers had 30 days to complete encounters or their practices would be closed to new patients; at 30 days, noncompliant providers had 60 days before practice suspension. During cycle 3 (May to September 2016), we continued to monitor and send targeted e-mails to providers who accumulated > 50 encounters. We modeled the financial impact of the intervention using net closure data, the report’s aging function, and billing logs. Results: InBasket monitoring with structured feedback decreased open encounters by 53.43%. We did not see improvements in the other metrics that the report tracked. We estimate that $231,724 was saved as a result of the intervention and $349,179 was lost to filing deadlines. Conclusion: Automated e-mails did not reduce open encounters; targeted e-mails to providers improved InBasket management.

  • Monitoring inbaskets with feedback to providers enhances the timeliness of patient care.

    by Kerin B. Adelson, Amelia Anne Trant, Michael Strait, Rory Kaplan, Vanna Dest, Adam Roshka, Catherine A. Lyons, Kevin A. Vest, Tessa Steffen, Rogerio Lilenbaum

    132 Background: The adoption of Electronic Health Records (EHRs) has changed the workflow for providers. The “inBasket” feature supplants telephone and email communications, replaces paper results review and has become the way to track incomplete encounters. Failure to promptly complete medical records leads to unread notes and impairs multidisciplinary communication. Also, unclosed encounters lead to potential penalties and uncollected fees. One benefit of the inBasket, is that it can be monitored. Methods: We created a report that tracked EPIC inBasket activities by provider including numbers of open charts, unchecked results, phone calls, incomplete dictations and orders needing cosign. The report shows the number and length of time each activity has been delinquent. In December 2015 we began emailing automated reports to all providers with their monthly results. In January 2016 we began an enforcement process for providers with >50 open charts: 30 days to complete charts or practice would be closed to new patients; if >50 remained after 30 days providers had 60 days before complete suspension from practice. We modeled the financial impact of chart closure by creating a weighted average by payor of fees collected per visit. For charts that would have been delinquent beyond payor filing deadlines this represents actual increased revenue. For charts that would have eventually been closed before the filing deadline this represents earlier revenue capture. Results: See table. Conclusions: Inbasket monitoring with structured feedback to providers led to improvement in the number of open charts, the focus of corrective action. We did not see consistent improvements in the other inbasket metrics. Future work will involve a similar approach to all inBasket metrics. Closing charts also has a significant financial impact; we estimate that $483,049 in fees that could have been lost due to exceeding payor deadlines became collectable. [Table: see text]

  • An EPIC electronic decision support tool to identify percentage of patients with stage IV thoracic or gastrointestinal malignancy who would benefit from concurrent palliative care but do not currently receive it.

    by Kerin B. Adelson, Amelia Anne Trant, Kim Framski, Mark Swidler, Nitu Kashyap

    133 Background: In 2016 ASCO updated its guideline for early integration of palliative care (PC) into standard oncologic care for all “inpatients and outpatients with advanced cancer.” PC has been shown to improve quality of life, align care at the end of life with patient preferences, and reduce health-care utilization. In preparation for the expansion of our palliative care service into ambulatory disease-based practices at Smilow Cancer Hospital at Yale-New Haven, we sought to create a decision support tool (DST) in the EPIC Electronic Health Record (EHR) that would identify patients for PC referral. Methods: This DST identifies patients with a GI or thoracic malignancy who have had an ICD-10 diagnosis of metastatic or stage IV disease, have not had a palliative care visit in the last 6 months, and are not enrolled in hospice. If the patient meets criteria, the DST will remind providers that “this patient meets ASCO and IOM criteria for concurrent palliative care with oncologic care ” and offers a one-click option to place the referral. To understand the volume of patients this DST would refer, we ran it silently in the EHR background from 7/15/16 through 9/1/16. We tracked how many patients were seen in the clinics, how many were eligible, and how many were referred to PC. Results: See table. Conclusions: Our silent BPA indicated that only 5% of patients eligible for a palliative care consult received it at baseline; this matches national data, which suggests that most patients who would benefit from PC do not receive it. This DST has the potential to dramatically improve PC referral rates and increase adherence with ASCO and IOM guidelines. We plan to move the DST into the live clinical EHR in 2017 after the integrated PC clinics are open. We anticipate that once our BPA is activated, we will see a dramatic increase in the number of eligible patients referred to palliative care. [Table: see text]